Selecting Good 'Drug-Like' Properties to Optimize Small Molecule Blood-Brain Barrier Penetration

被引:28
作者
Trippier, Paul C. [1 ,2 ]
机构
[1] Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, 1300 S Coulter, Amarillo, TX 79106 USA
[2] Texas Tech Univ, Dept Chem & Biochem, Ctr Chem Biol, Lubbock, TX 79409 USA
关键词
Blood-brain barrier; Drug-likeness; Central Nervous System; Neuropharmacology; Physicochemical Properties; Drug Design; CENTRAL-NERVOUS-SYSTEM; IN-SILICO PREDICTION; PLASMA-CONCENTRATION RATIO; P-GLYCOPROTEIN; ENDOTHELIAL-CELLS; ADME EVALUATION; UNBOUND BRAIN; VITRO MODELS; PASSIVE PERMEABILITY; SLICE METHOD;
D O I
10.2174/0929867323666160405112353
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The success rate to achieve clinical approval of drugs developed to treat diseases of the central nervous system (CNS) is the lowest of all disease indications. A large contributor to this poor success rate is failure of small molecules to pass through the blood-brain barrier (BBB), a barrier composed of capillary endothelial cells connected by tight junctions that functions to extrude xenobiotics from the brain. Designing small molecules to be BBB penetrant has been the subject of intensive research and has resulted in a series of guidelines to attain the best possible chances of BBB penetration. This review will analyze the current state of thinking in ranking the importance of various physicochemical properties required to select BBB penetrant molecules, describe model systems to determine BBB penetration, summarize data analysis methods and provide an outlook on further developments in the field.
引用
收藏
页码:1392 / 1407
页数:16
相关论文
共 141 条
  • [1] Blood-brain barrier structure and function and the challenges for CNS drug delivery
    Abbott, N. Joan
    [J]. JOURNAL OF INHERITED METABOLIC DISEASE, 2013, 36 (03) : 437 - 449
  • [2] Overview and introduction: The blood-brain barrier in health and disease
    Abbott, N. Joan
    Friedman, Alon
    [J]. EPILEPSIA, 2012, 53 : 1 - 6
  • [3] Structure and function of the blood-brain barrier
    Abbott, N. Joan
    Patabendige, Adjanie A. K.
    Dolman, Diana E. M.
    Yusof, Siti R.
    Begley, David J.
    [J]. NEUROBIOLOGY OF DISEASE, 2010, 37 (01) : 13 - 25
  • [4] The factors that influence permeation across the blood-brain barrier
    Abraham, MH
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2004, 39 (03) : 235 - 240
  • [5] An invertebrate model for CNS drug discovery: Transcriptomic and functional analysis of a mammalian P-glycoprotein ortholog
    Al-Qadi, Sonia
    Schiott, Morten
    Hansen, Steen Honore
    Nielsen, Peter Aadal
    Badolo, Lassina
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2015, 1850 (12): : 2439 - +
  • [6] Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery
    Alavijeh M.S.
    Chishty M.
    Qaiser M.Z.
    Palmer A.M.
    [J]. NeuroRX, 2005, 2 (4): : 554 - 571
  • [7] Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
    Aller, Stephen G.
    Yu, Jodie
    Ward, Andrew
    Weng, Yue
    Chittaboina, Srinivas
    Zhuo, Rupeng
    Harrell, Patina M.
    Trinh, Yenphuong T.
    Zhang, Qinghai
    Urbatsch, Ina L.
    Chang, Geoffrey
    [J]. SCIENCE, 2009, 323 (5922) : 1718 - 1722
  • [8] Controlled Ultrasound-Induced Blood-Brain Barrier Disruption Using Passive Acoustic Emissions Monitoring
    Arvanitis, Costas D.
    Livingstone, Margaret S.
    Vykhodtseva, Natalia
    McDannold, Nathan
    [J]. PLOS ONE, 2012, 7 (09):
  • [9] Asotra Kamlesh, 2003, Methods Mol Med, V89, P177
  • [10] Deleterious effects of reactive metabolites
    Attia, Sabry M.
    [J]. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2010, 3 (04) : 238 - 253